Project Grant R43CA254597

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is supporting research at Boston Children's Hospital to develop a novel precision immunotherapy strategy using genetically engineered tumor-specific B cells. The $249,645 grant, awarded on January 1, 2025, will fund investigations into leveraging homology-driven gene editing to rapidly generate B cells targeting the HER2 tumor antigen. The research aims to evaluate the efficacy and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The total funding amount is $1,001,029 for the period from September 20, 2024 to August 31, 2026. The key products or services to be delivered under this award include: 1) Generation of a GMP-grade master cell bank and viral particles for the IMT-422 (CD4...

This $628,499 Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research program) supports research to develop innovative mRNA vaccines for enhancing the efficacy of T-cell transfer therapies against solid tumors, with a focus on pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this 5-year grant include: 1) engineering new mRNA vaccines targeting clinically relevant tumor antigens (mesothelin and mutant KRAS) and...

The National Cancer Institute awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The Regents of the University of California, San Francisco (UCSF) to develop a bispecific T cell engager targeting the tumor-specific antigen ALPPL2. The $544,866 grant aims to generate and optimize ALPPL2-targeted bispecific T cell engagers, evaluate their tumor-specific cytotoxicity and cytokine release, and identify a lead candidate for clinical translation. UCSF, a prominent...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,669 to Immunoblue, LLC to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key product being developed is an autologous ATCT that targets multiple GBM-specific antigens in each patient. This is achieved by applying Prussian blue...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $215,311 to the University of Texas Health Science Center at Houston to conduct preclinical research on antibody-drug conjugates (ADCs) targeting the GPR56 protein for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) Generate and evaluate the cell-killing efficacy of GPR56-targeted ADCs in TNBC cell lines; 2) Assess the safety and efficacy of the lead...

The National Cancer Institute awarded a $417,858 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Brigham & Women's Hospital Inc. to develop novel cellular therapies for the treatment of glioblastoma (GBM), a highly malignant brain tumor. The project aims to engineer mesenchymal stem cells (MSCs) to release bi-specific T cell engager (BiTE) molecules targeting EGFR/EGFRvIII and IL13Rα2 antigens expressed on GBM cells. The engineered MSCs will be encapsulated in a synthetic...

This Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program provides $218,089 to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel Rac-Enhanced Chimeric Antigen Receptor Macrophage (RACE-CAR-M) immunotherapy for triple-negative breast cancer (TNBC). The key products and services to be delivered under this 4/1/2025 to 3/31/2027 award include: Evaluating the specificity, efficacy, and anti-angiogenic potential of...

This $131,220 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support cancer vaccine research under the Cancer Research Manpower federal grant program (CFDA 93.398). The grant recipient, Stanford University, will develop a new approach to cancer vaccination that directly reprograms cancer cells into antigen presenting cells (APCs) through mRNA-enabled cell reprogramming. Researchers aim to overcome barriers to current vaccination...

This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...